Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity

Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity

US Patent 11389469 · Granted Jul 19, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Nicotinamide mononucleotide derivatives and their uses2025
Cellular reprogramming to reverse aging and promote organ and tissue regeneratio2025
Cellular reprogramming to reverse aging and promote organ and tissue regeneratio2025
Cellular reprogramming to reverse aging and promote organ and tissue regeneratio2025
SIRT1 activating compounds2025
Modulating Nudix homology domain (NHD) with nicotinamide mononucleotide analogs 2024
Nicotinamide mononucleotide derivatives and their uses2024
Systems and methods for genomic manipulations and analysis2023
Depth codec for real-time, high-quality light field reconstruction2023
Nicotinamide mononucleotide derivatives and their uses2022
Methods and systems for biological sequence compression transfer and encryption2022
Depth codec for real-time, high-quality light field reconstruction2021